AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 161 filers reported holding AIMMUNE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.95 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $53,357,000 | -3.9% | 3,193,117 | -17.1% | 1.16% | -35.5% |
| Q1 2020 | $55,531,000 | -46.2% | 3,851,000 | +24.9% | 1.80% | -38.2% |
| Q4 2019 | $103,221,000 | +59.8% | 3,084,000 | 0.0% | 2.91% | +36.3% |
| Q3 2019 | $64,579,000 | +11.8% | 3,084,000 | +11.1% | 2.13% | +21.5% |
| Q2 2019 | $57,776,000 | +31.8% | 2,775,000 | +41.4% | 1.76% | +16.4% |
| Q1 2019 | $43,851,000 | +5.4% | 1,962,000 | +12.8% | 1.51% | -18.1% |
| Q4 2018 | $41,597,000 | -12.3% | 1,739,000 | 0.0% | 1.84% | +5.7% |
| Q3 2018 | $47,440,000 | +8.9% | 1,739,000 | +7.3% | 1.74% | -3.7% |
| Q2 2018 | $43,562,000 | -12.5% | 1,620,000 | +3.5% | 1.81% | -22.5% |
| Q1 2018 | $49,813,000 | +7.4% | 1,564,983 | +27.6% | 2.33% | -3.5% |
| Q4 2017 | $46,367,000 | +81.6% | 1,226,000 | +19.0% | 2.42% | +67.0% |
| Q3 2017 | $25,534,000 | +20.6% | 1,030,000 | 0.0% | 1.45% | +9.8% |
| Q2 2017 | $21,177,000 | +214.4% | 1,030,000 | +232.3% | 1.32% | +195.5% |
| Q1 2017 | $6,736,000 | – | 310,000 | – | 0.45% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 3,100,146 | $117,248,000 | 40.96% |
| TLP GROUP LLC | 1,050,000 | $39,711,000 | 27.53% |
| Aisling Capital LLC | 2,240,000 | $84,717,000 | 16.74% |
| Foresite Capital Management III, LLC | 764,824 | $28,926,000 | 8.12% |
| AlpInvest Partners B.V. | 51,498 | $1,948,000 | 6.95% |
| Vivo Capital, LLC | 643,626 | $24,342,000 | 5.21% |
| GREAT POINT PARTNERS LLC | 573,550 | $21,692,000 | 3.70% |
| Eventide Asset Management | 1,226,000 | $46,367,000 | 2.42% |
| Palo Alto Investors LP | 1,146,419 | $43,358,000 | 1.87% |
| HAMILTON LANE ADVISORS LLC | 78,846 | $2,982,000 | 1.54% |